We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Breast, colon, prostate, and lung cancers did not stop for COVID-19 in 2020, but screenings and treatments did. Dramatically. The result, say doctors, could be a catastrophe in the making.
BridgeBio Pharma announced the launch of CoA Therapeutics, a biopharmaceutical company developing novel small-molecules designed to increase Coenzyme-A (CoA) levels in genetic disorders where CoA deficiency is implicated.